Keywords: iroko, acquires, rights, merck, co, cv, compound

Iroko acquires rights to Merck & Co CV compound

Article | 04 February 2008

Print This

Philadelphia, USA-based Iroko Pharmaceuticals has acquired all non-US commercial rights to Aggrastat (tirofiban HCl) from drug major Merck & Co.

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in